Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
Cukurova University Faculty of Medicine Research Hospital, Adana, Turkey
Departement d'anesthesie Hopital Armand Trousseau, Paris, France
Yeditepe University Hospital, Istanbul, Turkey
Cigdem Yildirim Guclu, Ankara, Turkey
Departement d'anesthesie Hopital Armand Trousseau, Paris, France
Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
Seoul National University Hospital, Seoul, Korea, Republic of
Gangnam Severance hospital, Seoul, Gangnam-gu, Korea, Republic of
Konkuk University Medical Center, Seoul, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.